Welcome to Psylin Neurosciences, Inc.

Psylin Neurosciences, Inc. was formed in January 2007 as a virtual biotech company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics Inc. Under this new venture, Psylin will evaluate the potential of peptide hormones as novel therapeutic approaches to psychiatric disorders. Psylin will have access to molecules in Amylin's proprietary polypeptide hormone library, known as PHORMOL™, and to PsychoGenics' proprietary drug discovery technologies. The combination of Amylin's peptide expertise and its manufacturing and peptide delivery knowledge with PsychoGenics' expertise in preclinical neuropharmacology provide Psylin with a unique drug discovery resource.

Psylin Neurosciences, Amylin’s Pysch-Drug Offspring, Nearing First Clinical Trial

April 27, 2009 — There are still great voids in understanding the effects of even approved psychiatric drugs. But there’s no doubt that the business of selling antidepressants and the like can be extremely lucrative. Psylin Neurosciences—a joint venture of San Diego-based Amylin Pharmaceuticals and New York drug research firm PsychoGenics—is very much a product of both of those realities.
Download PDF > | See All News >